Syneron Medical Ltd. (ELOS)
Q2 2012 Earnings Conference Call
August 15, 2012 8:30 am ET
Zack Kubow – The Ruth Group
Louis P. Scafuri – Chief Executive Officer
Asaf Alperovitz – Chief Financial Officer
Richard Newitter – Leerink Swann
Jeremy Feffer – Cantor Fitzgerald & Co.,
Anthony Vendetti – Maxim Group
Dalton Chandler – Needham & Company
Good day, ladies and gentlemen, and welcome to the Syneron Medical’s second quarter 2012 earnings results conference call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the call over to your host, Zack Kubow with The Ruth Group. You may begin.
Thank you, operator. I would like to welcome you to Syneron Medical’s second quarter 2012 conference call. Statements on this call may be forward-looking within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 relating to the company’s future events or future performance, including statements with respect to Syneron’s expectations regarding, but not limited to the financial forecast for 2012, the launch of new products and the maintenance of a leadership position in core and non-core markets.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in any forward-looking statements. These risks may include, but are not limited to the risk factors set forth under the heading Risk Factors in Syneron’s Annual Report on Form 20-F, filed with the SEC. These factors are updated from time to time through the filing of reports and registration statements with the Securities and Exchange Commission. These statements are only predictions and Syneron cannot guarantee that they will, in fact, occur. The company does not assume any obligation to update the forward-looking statements discussed in today’s conference call.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts